Q-omics provides the consensus-scored CRYGEP profile across patient tissues and cancer cell-line models. CRYGEP expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CRYGEP is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, CRYGEP RNA expression shows 11,703 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, PRAD, and TGCT as cancer lineages where CRYGEP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYGEP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYGEP survival associations across molecular data types. CRYGEP RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYGEP RNA expression–survival associations across cancer types. High CRYGEP expression shows unfavorable associations in COAD, ESCA, PCPG, SKCM and LAML, but favorable associations in LUSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CRYGEP RNA expression.
This table summarizes CRYGEP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for CRYGEP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYGEP shows lower tumor expression in PRAD. The PRAD box plot shows higher CRYGEP RNA expression in normal versus tumor tissue (log2 FC = −0.087, t-test p = .007).
This table shows molecular features associated with CRYGEP in patient tissues and cancer cell lines. In patient samples, CRYGEP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
